Summary:
Are you a patient with moderate to severe plaque psoriasis? Have you treated your condition with adalimumab (Humira®) and has it become less effective on your plaque psoriasis within the last 6 months? If so, you may be eligible for a clinical research study with etanercept (Enbrel®) which is also approved for moderate to severe plaque psoriasis.
Qualified Participants Must:
• 18 years of age or older
•
Be diagnosed with moderate to severe plaque psoriasis
•
Have lost a satisfactory response to adalimumab:
i.e., currently taking adalimumab but it has stopped helping your psoriasis
OR, you were taking adalimumab within the past 6 months and stopped
because of loss of effectiveness
•
Not be pregnant, breastfeeding, or planning to become pregnant for the duration of the study and for 4 weeks after the end of treatment
Qualified Participants May Receive:
Etanercept (Enbrel), study-related tests, exams, medical care related to the study from board-certified physicians and be reimbursed for expenses associated with study visits, such as travel expenses.